1-(苯磺酰基)-4-氟吲哚 | 102855-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(苯磺酰基)-4-氟吲哚
• 英文名称: 4-fluoro-1-(phenylsulfonyl)-1H-indole
• 英文别名: 1H-Indole, 4-fluoro-1-(phenylsulfonyl)-；1-(benzenesulfonyl)-4-fluoroindole
• CAS: 102855-23-2
• 化学式: C₁₄H₁₀FNO₂S
• 分子量: 275.303
• InChiKey: VQFCRMTYLDNSMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(苯磺酰基)-4-氟吲哚 在 四丁基氟化铵 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正庚烷 为溶剂， 反应 1.0h， 生成 (5-benzyloxy-1H-indol-2-yl)-(4-fluoro-1H-indol-2-yl)methanone
  参考文献：
  名称：

  Novel Bis(1H-indol-2-yl)methanones as Potent Inhibitors of FLT3 and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

  摘要：

  FLT3 receptor tyrosine kinase is aberrantly active in many cases of acute myeloid leukemia (AML). Recently, bis(1H-indol-2-yl) methanones were found to inhibit FLT3 and PDGFR kinases. To optimize FLT3 activity and selectivity, 35 novel derivatives were synthesized and tested for inhibition of FLT3 and PDGFR autophosphorylation. The most potent FLT3 inhibitors 98 and 102 show IC50 values of 0.06 and 0.04 mu M, respectively, and 1 order of magnitude lower PDGFR inhibiting activity. The derivatives 76 and 82 are 20- to 40- fold PDGFR selective. Docking at the recent FLT3 structure suggests a bidentate binding mode with the backbone of Cys-694. Activity and selectivity can be related to interactions of one indole moiety with a hydrophobic pocket including Phe-691, the only different binding site residue (PDGFR Thr-681). Compound 102 inhibited the proliferation of 32D cells expressing wildtype FLT3 or FLT3-ITD similarly as FLT3 autophosphorylation, and induced apoptosis in primary AML patient blasts.

  DOI：

  10.1021/jm058033i
• 作为产物：
  描述：

  1-(benzenesulfonyl)indole-4-diazonium;tetrafluoroborate 生成 1-(苯磺酰基)-4-氟吲哚
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS IMIDAZO-PYRIDINE À UTILISER EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019077631A1

  公开（公告）日：2019-04-25

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在本文中被描述。本文描述的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。还描述了制备公式（I）、（II）和（III）的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物的过程，以及包含公式（I）、公式（II）、公式（III）的化合物或其药学上可接受的盐的药物组合物。
• [EN] HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019058393A1

  公开（公告）日：2019-03-28

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在此处描述。本文描述的化合物及其多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。
• Surprising Repair Activities of Nonpolar Analogs of 8-oxoG Expose Features of Recognition and Catalysis by Base Excision Repair Glycosylases
  作者：Paige L. McKibbin、Akio Kobori、Yosuke Taniguchi、Eric T. Kool、Sheila S. David

  DOI：10.1021/ja208510m

  日期：2012.1.25

  glycosylases locate and excise damaged bases from DNA, playing central roles in preservation of the genome and prevention of disease. Two key glycosylases, Fpg and hOGG1, function to remove the mutagenic oxidized base 8-oxoG (OG) from DNA. To investigate the relative contributions of conformational preferences, leaving group ability, enzyme-base hydrogen bonding, and nucleobase shape on damage recognition

  修复糖基化酶从 DNA 中定位和切除受损的碱基，在基因组保存和疾病预防中发挥核心作用。两个关键的糖基化酶 Fpg 和 hOGG1 的作用是从 DNA 中去除诱变的氧化碱基 8-oxoG (OG)。为了研究构象偏好、离去基团能力、酶基氢键和核碱基形状对这些糖基化酶损伤识别的相对贡献，一系列四个取代的吲哚核苷，基于亲本 OG 非极性等排体 2Cl-4F-吲哚，在与 C 配对的 30 个碱基对双链体的背景下，作为这些酶的可能直接底物进行了测试。令人惊讶的是，单周转实验表明，Fpg 催化的两种非极性类似物的碱基去除活性优于天然 OG 底物。还发现 hOGG1 糖基化酶可催化去除三种非极性类似物，但效率远低于去除 OG。值得注意的是，完全耐受 hOGG1 催化切除的类似物在 OG 的 NH7 位置有一个氯取代基，这意味着在催化中识别该位置的重要性。hOGG1 和 Fpg 都保留了对含有非极性等排体的双链体的高亲和力。这些研究表明，Fpg
• Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
  作者：Han-Jie Zhou、Jinhai Wang、Bing Yao、Steve Wong、Stevan Djakovic、Brajesh Kumar、Julie Rice、Eduardo Valle、Ferdie Soriano、Mary-Kamala Menon、Antonett Madriaga、Szerenke Kiss von Soly、Abhinav Kumar、Francesco Parlati、F. Michael Yakes、Laura Shawver、Ronan Le Moigne、Daniel J. Anderson、Mark Rolfe、David Wustrow

  DOI：10.1021/acs.jmedchem.5b01346

  日期：2015.12.24

  The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin proteasome system (ups) mediated protein degradation, endoplasmic reticulum-associated degradation (BRAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-6083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell, death. In tumor bearing mice, oral administration of 71 causes rapid accumulation Of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to Sustained antitumor activity in in vivo, xenograft models of both solid and hematological tumors. 71 has been taken into phase I clinical trials in patients with multiple myeloma and solid tumors.
• ——
  作者：MATSUMOTO MASAKATSU、 XATANAKA NAOXITO、 ISIDA YASUKO

  DOI：——

  日期：——